|Univariate and multivariate analyses for sustained virologic response to the combination therapy with peginterferon and ribavirin in patients who underwent response guided therapy according to the AASLD guidelines|
|Univariate analysis||Multivariate analysis*||Odds ratio (95% confidence interval)|
|Age (years)||< 0.001||N.S.|
|BMI, median (range)||N.S.|
|Prior treatment for HCV (no/yes)||N.S.|
|Pretreatment HCV RNA levels (log10 IU/mL), (≤6.0 vs. 6.0<)||0.015||0.013||2.235 (1.189-4.203)|
|Platelet count (×103/μL)||< 0.001||0.011||1.007 (1.002-1.013)|
|Neutrophil count (/μL)||0.003||N.S.|
|Alanine aminotransferase (IU/L)||N.S.|
|γ-glutamyl transpeptidase (IU/L)||0.014||N.S.|
|Fibrosis score (F1 or F2/F3 or F4)||< 0.001||N.S.|
|Activity score (A1 or A2/A3 or A4)||0.002||N.S.|
|Genetic polymorphisms of rs8099917 (TT/GG or TG)||< 0.001||< 0.001||5.782 (2.298-14.552)|
|Amino acid at residue 70 of HCV core (arginine/glutamine or histidine)||< 0.001||N.S.|
|Amino acid sequence of ISDR (non-wild-type/wild-type)||< 0.001||0.038||2.077 (1.041-4.147)|
|Reduction of HCV RNA [Pre - 4 week] (log10 IU/mL), (≤2.8 vs. 2.8<)||< 0.001||< 0.001||3.911 (1.935-7.908)|
|Reduction of HCV RNA [Pre - 12 week] (log10 IU/mL), (≤4.9 vs. 4.9<)||< 0.001||0.013||2.578 (1.220-5.448)|
*Multivariate analysis was performed on 314 patients in whom all variables were available.
(N = 516).
Toyoda et al.
Toyoda et al. BMC Infectious Diseases 2012 12:324 doi:10.1186/1471-2334-12-324